An experimental vaccine using a novel defense mechanism could eventually help treat sufferers of a common virus that affects more than half of the U.S. population and causes congenital birth defects in some cases.
Having ticked candidates to protect against respiratory syncytial virus, dengue and norovirus off its list of areas of interest as part of its plans to establish a global vaccine business, Takeda has invested in another stated target: cytomegalovirus.
A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.
San Diego-based Vical recruited 390 patients to test Allovectin (velimogene aliplasmid), a cancer immunotherapy that's been in the clinic for years. The biotech had been bullish about its Phase II data. The company didn't disclose any data this morning, saying that it would release results at a later scientific conference.
Last month's cancellation of the largest ongoing HIV vaccine trial stopped yet another promising candidate. The growing pool of clinical failures shows that a new approach is needed. This past week, academia offered up two new angles of attack.
While the cancer-virus link is nothing new, researchers previously believed only 20% of cancers were virus-caused. Now a new study has found that up to 40% of cancers could originate in a viral
Human cytomegalovirus is a clearly defined threat. At its worst the virus triggers congenital malformations in newborns, as well as lethal threats to transplant recipients and AIDS patients--two
An experimental vaccine cut the rate of cytomegalovirus infections in young women by half in a mid-stage trial, and the researchers involved say that it may well significantly reduce instances of a